Filing Flows › AtriCure (ATRC) › Q2 2026 › vs Q1 2026
AtriCure (ATRC) Q2 2026 vs Q1 2026 (quarter over quarter)
AtriCure's revenue rose $12.4M (+9%) from $141M in Q1 2026 to $154M in Q2 2026. Gross margin 77.2% against 77.4% (-0.2 pts).
AtriCure, Q2 2026: revenue $154M (+13% year over year), operating margin 6.3%, net earnings $9.0M, operating cash flow $22.2M. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Gross margin | 77.2% | 77.4% | -0.2 pts |
| Operating margin | 6.3% | 0.4% | +5.9 pts |
| Net margin | 5.8% | 0.1% | +5.8 pts |
| Free cash flow margin | 12.0% | -5.6% | +17.6 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $154M | $141M | $12.4M | +9% |
| Gross profit | $119M | $109M | $9.3M | +9% |
| Cost of revenue | $35.0M | $31.9M | $3.0M | +10% |
| Operating profit | $9.7M | $526K | $9.1M | 18× |
| Operating expenses | $109M | $109M | $179K | +0.2% |
| Pre-tax earnings | $9.4M | $394K | $9.0M | 24× |
| Research & development | $26.4M | $24.2M | $2.2M | +9% |
| SG&A | $82.6M | $84.5M | −$2.0M | -2% |
| Net earnings | $9.0M | $108K | $8.8M | 83× |
| Income tax | $471K | $286K | $185K | +65% |
| Depreciation & amortization | $5.3M | $5.3M | $34K | +0.6% |
| Share-based compensation | $12.3M | $11.3M | $1.0M | +9% |
| Working capital & other | $4.4M | $20.6M | −$16.3M | -79% |
| Operating cash flow | $22.2M | −$4.0M | $26.2M | — |
| Free cash flow (OCF − capex) | $18.4M | −$7.8M | $26.3M | — |
| Capital expenditures | $3.8M | $3.9M | −$86K | -2% |
Questions
How much did AtriCure's revenue grow quarter over quarter in Q2 2026?
AtriCure's revenue rose $12.4M (+9%) from $141M in Q1 2026 to $154M in Q2 2026. Gross margin 77.2% against 77.4% (-0.2 pts).